FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3129381400> ?p ?o ?g. }

• W3129381400 endingPage "e578" @default.
• W3129381400 startingPage "e569" @default.
• W3129381400 abstract "Classic BCR/ABL1-negative myeloproliferative neoplasms (MPNs) are characterized by clinical and genetic heterogeneity and include 4 distinct constituents. Very little data on clinical presentation and epidemiology of the same is available from the Indian setting.Patients referred to Hematology-Oncology from January 2018 to August 2020 with suspected MPNs were included in the analysis and prospectively followed-up. All patients were initially screened, and only those meeting the updated World Health Organization 2016 criteria were included in the analysis. Epidemiologic, clinical, and molecular characteristics were documented, and patients were followed-up prospectively.A total of 233 patients were referred for evaluation of MPN, of which 63 were included in the analysis, including 39 males and 24 females. The median age at diagnosis was 57 years (range, 28-82 years), and 38% patients were younger than 50 years of age. The most common presentations were incidental detection in 35 (55.5%), abdominal symptoms in 13 (20%), fatiguability in 7 (11%), and recent vascular events in 6 (9.5%) patients. Final diagnosis was polycythemia vera in 27, essential thrombocytosis (ET) in 21, prefibrotic myelofibrosis in 9, and myelofibrosis in 6 patients. The frequency of driver mutations in polycythemia vera included JAK2 in 75%; in ET, JAK2 in 33%, CALR in 33%, and MPL in 4%; and in prefibrotic myelofibrosis, JAK2 in 66% and CALR in 33%. Aspirin was used for all patients along with risk-adapted cytoreduction with hydroxyurea. Ruxolitinib was reserved for symptoms refractory to hydroxyurea. After a median follow-up of 15 months (interquartile range, 10-28 months) from diagnosis, disease progression was noted in 4 patients. Two patients died at the end of the follow-up period, including 1 with secondary acute myeloid leukemia post myelofibrosis and one with ET and coexistent oral malignancy. The remaining 61 patients are alive and on regular treatment.This is one of the first systematic descriptions and prospective follow-up of patients with BCR/ABL-negative MPNs from India. Our study indicates a younger median age of presentation and higher proportion of JAK2-unmutated disease across all subtypes. The primary role of bone marrow morphology and supportive role of somatic mutations in differentiating MPN subtypes is indicated.This study sets the stage for a collaborative registry for defining epidemiologic data and long-term outcomes with MPN in India." @default.
• W3129381400 created "2021-03-01" @default.
• W3129381400 creator A5004659734 @default.
• W3129381400 creator A5006643568 @default.
• W3129381400 creator A5017525996 @default.
• W3129381400 creator A5021718749 @default.
• W3129381400 creator A5031281211 @default.
• W3129381400 creator A5033166943 @default.
• W3129381400 creator A5040424738 @default.
• W3129381400 creator A5065519573 @default.
• W3129381400 creator A5067303805 @default.
• W3129381400 date "2021-06-01" @default.
• W3129381400 modified "2023-09-27" @default.
• W3129381400 title "Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges" @default.
• W3129381400 cites W2004841640 @default.
• W3129381400 cites W2007684724 @default.
• W3129381400 cites W2033914091 @default.
• W3129381400 cites W2070959673 @default.
• W3129381400 cites W2072881492 @default.
• W3129381400 cites W2126665281 @default.
• W3129381400 cites W2127559749 @default.
• W3129381400 cites W2145187040 @default.
• W3129381400 cites W2149055075 @default.
• W3129381400 cites W2149927396 @default.
• W3129381400 cites W2199176947 @default.
• W3129381400 cites W2339658711 @default.
• W3129381400 cites W2369154184 @default.
• W3129381400 cites W2617064728 @default.
• W3129381400 cites W2759518054 @default.
• W3129381400 cites W2768301539 @default.
• W3129381400 cites W2791464448 @default.
• W3129381400 cites W2805661432 @default.
• W3129381400 cites W2897503951 @default.
• W3129381400 cites W2903156594 @default.
• W3129381400 cites W2917495513 @default.
• W3129381400 cites W2937668244 @default.
• W3129381400 cites W2942281852 @default.
• W3129381400 cites W2970831199 @default.
• W3129381400 cites W2975603087 @default.
• W3129381400 doi "https://doi.org/10.1016/j.clml.2021.01.017" @default.
• W3129381400 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33757770" @default.
• W3129381400 hasPublicationYear "2021" @default.
• W3129381400 type Work @default.
• W3129381400 sameAs 3129381400 @default.
• W3129381400 citedByCount "2" @default.
• W3129381400 countsByYear W31293814002022 @default.
• W3129381400 countsByYear W31293814002023 @default.
• W3129381400 crossrefType "journal-article" @default.
• W3129381400 hasAuthorship W3129381400A5004659734 @default.
• W3129381400 hasAuthorship W3129381400A5006643568 @default.
• W3129381400 hasAuthorship W3129381400A5017525996 @default.
• W3129381400 hasAuthorship W3129381400A5021718749 @default.
• W3129381400 hasAuthorship W3129381400A5031281211 @default.
• W3129381400 hasAuthorship W3129381400A5033166943 @default.
• W3129381400 hasAuthorship W3129381400A5040424738 @default.
• W3129381400 hasAuthorship W3129381400A5065519573 @default.
• W3129381400 hasAuthorship W3129381400A5067303805 @default.
• W3129381400 hasConcept C119060515 @default.
• W3129381400 hasConcept C126322002 @default.
• W3129381400 hasConcept C141071460 @default.
• W3129381400 hasConcept C2776112149 @default.
• W3129381400 hasConcept C2778837598 @default.
• W3129381400 hasConcept C2779788118 @default.
• W3129381400 hasConcept C2780007613 @default.
• W3129381400 hasConcept C2780076729 @default.
• W3129381400 hasConcept C2780829020 @default.
• W3129381400 hasConcept C2781057849 @default.
• W3129381400 hasConcept C2781107747 @default.
• W3129381400 hasConcept C71924100 @default.
• W3129381400 hasConcept C89560881 @default.
• W3129381400 hasConcept C90924648 @default.
• W3129381400 hasConceptScore W3129381400C119060515 @default.
• W3129381400 hasConceptScore W3129381400C126322002 @default.
• W3129381400 hasConceptScore W3129381400C141071460 @default.
• W3129381400 hasConceptScore W3129381400C2776112149 @default.
• W3129381400 hasConceptScore W3129381400C2778837598 @default.
• W3129381400 hasConceptScore W3129381400C2779788118 @default.
• W3129381400 hasConceptScore W3129381400C2780007613 @default.
• W3129381400 hasConceptScore W3129381400C2780076729 @default.
• W3129381400 hasConceptScore W3129381400C2780829020 @default.
• W3129381400 hasConceptScore W3129381400C2781057849 @default.
• W3129381400 hasConceptScore W3129381400C2781107747 @default.
• W3129381400 hasConceptScore W3129381400C71924100 @default.
• W3129381400 hasConceptScore W3129381400C89560881 @default.
• W3129381400 hasConceptScore W3129381400C90924648 @default.
• W3129381400 hasIssue "6" @default.
• W3129381400 hasLocation W31293814001 @default.
• W3129381400 hasLocation W31293814002 @default.
• W3129381400 hasOpenAccess W3129381400 @default.
• W3129381400 hasPrimaryLocation W31293814001 @default.
• W3129381400 hasRelatedWork W1990387953 @default.
• W3129381400 hasRelatedWork W2007651804 @default.
• W3129381400 hasRelatedWork W2088272024 @default.
• W3129381400 hasRelatedWork W2517872353 @default.
• W3129381400 hasRelatedWork W2558450558 @default.
• W3129381400 hasRelatedWork W2573364227 @default.
• W3129381400 hasRelatedWork W2810533269 @default.
• W3129381400 hasRelatedWork W3129381400 @default.

• next